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Background: Metabolic syndrome (Mets) is a cluster of cardiovascular risk factors which can predicts cardiovascular
disease (CVD). Carotid intima-media thickness (CIMT) is known as a surrogate measure of subclinical atherosclerosis
and predictor of CVD. Although, it has shown the association between Mets and CIMT, this relation regarding sex
differences is limited. We aimed to find out whether gender differences in this association.
Methods: In this cross-sectional study, we recorded height, weight, waist circumference (WC), blood pressure, and
lipid profiles. We used Mets; defined based on NCEP ATP III definition, and traditional cardiovascular risk factors; age,
body mass index (BMI), WC, hyperlipidemia, and hypertension, in multivariate regression models which including;.
The CIMT measurement < 0.73 or ≥0.73 mm was considered as low- or high risk to CVD.
Results: Overall, 150 subjects were enrolled to study that their ages were 36-75 years. The 47.3% of them
(71 subjects) had Mets. CIMT was increased in Mets group compared non-Mets group (P = 0.001). In logistic
regression analysis, a significant association was found between Mets and CIMT in women, but not in men
(p = 0.002, and p = 0.364, respectively). After adjustment to age, WC, BMI, hypertension and hyperlipidemia, this
association was significant just in women (p = 0.011) independent of WC, BMI, hyperlipidemia and hypertension.
Conclusion: Our data showed that MetS is a stronger risk factor for subclinical atherosclerosis in women than in
men. So, we suggest the assessment of CIMT along with definition Mets in middle-aged women could be lead to
earlier detection of at risk individuals to CVD.
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Metabolic syndrome (MetS) is defined as a cluster of
cardiovascular risk factors including central obesity,
hypertension, dyslipidemia, and glucose intolerance [1].
It has been shown that MetS is a predictor of type 2 dia-
betes mellitus (T2DM) [2] and cardiovascular disease
(CVD) [3]. MetS is associated with an approximately
two fold increase in CVD [4]. The Third National Health
and Nutrition Examination Survey (TNHNES) reported
that the prevalence of MetS was 24% in adults older
than 20 years and 42% in individuals aged 70 years or* Correspondence: fakhrzad@tums.ac.ir
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distribution, and reproduction in any mediumolder [5]. Its age-adjusted prevalence among adults aged
25- 64 years who participated in the MONICA WHO
Study in Iran was estimated at 27.5% [6]. The prevalence
was significantly higher in women than in men (35.9%
vs. 20.3%).
Carotid artery intima-media thickness (CIMT) is a
non-invasive surrogate marker of atherosclerosis [7]. Its
progression is influenced by conventional CVD risk fac-
tors [8]. Measurement of CIMT can directly predict the
risk of future cardiovascular events [8]. Increasing age,
male gender, hypertension, obesity, and T2DM or glu-
cose intolerance are associated with accelerated athero-
sclerosis in the carotid arteries [8].
Several studies have reported an association between
MetS and increased CIMT [9-13]. It has been suggesteded Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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women than in men [14,15], although there are other
reports which do not confirm this finding [12,16]. To
our knowledge possible sex differences regarding this
issue have not been studied in Iran and we aimed to
investigate this subject in a cross-sectional survey.
Methods
Study population
We used data from a subgroup of participants who were
enrolled in the Rapid Atherosclerosis Prevention In
Diabetes (RAPID) study. The RAPID study is an ongoing
prospective single-center cohort study in subjects aged
≥30 years and without any clinical evidence of coronary
artery disease (Minnesota codes 1.2.1, 1.2.4, 1.2.5, and
1.2.7) at the time of the investigation. This study was
started in September 2010 at Dr. Shariati Hospital/
Tehran University of Medical Sciences (TUMS), for
early detection of atherosclerosis in T2DM patients.
Written informed consent was obtained from all partici-
pants. The study was approved by the ethics committee
of the TUMS. In the present study we compared carotid
stiffness between subjects with and without MetS. Parti-
cipants with clinical evidence of coronary artery disease;
angina, positive ST elevation in ECG, or CVD end-
points such as myocardial infarction (MI) or stroke were
excluded. We recorded characteristics of 150 partici-
pants of whom 71 (47.3%) suffered from MetS. Mean
age of the participants was 49.8 ± 7.5 years (range:
39 years).
Definitions
Mets was diagnosed according to NCEP ATP III guide-
lines [1]. According to NCEP ATP III definition, MetS was
confirmed if at least three of the following criteria were
present: waist circumference (WC) ≥102 cm (in men) or
≥88 cm (in women), triglyceride ≥150 mg/dl or a history
of previous treatment for dyslipidemia, HDL cholesterol
≤40 mg/dl (in men) or ≤50 mg/dl (in women), blood pres-
sure ≥130/85 mmHg or those who had been treated for
hypertension, and fasting blood sugar (FBS)≥ 110 mg/dl
or a history of previous treatment for diabetes [1].
CVD is a group of heart and blood vessel disorders
that include coronary heart disease, cerebrovascular dis-
ease, peripheral arterial disease, and congenital heart dis-
ease, etc [17].
Heart attacks and strokes are usually acute events caused
by a blockage that prevents blood from flowing to the heart
or brain. The most common reason is a build-up of fatty
deposits on the inner walls of the blood vessels [17].
The term MI reflects cell death of cardiac myocytes
which is caused by ischemia. In other words it is the re-
sult of a perfusion imbalance between supply and de-
mand. MI should be diagnosed by symptoms, ECGabnormalities and enzymes, specific serological biomar-
kers and imaging [18].
Angina (or angina pectoris) is a symptom of coronary
artery disease caused by reduced blood flow to the heart
muscle leading to chest pain [19].
Conventional cardiovascular risk factors
Hypertension, WC, and hyperlipidemia were defined
according to NCEP ATP III guidelines [1]. In each sub-
ject (at standing position), WC was measured with a
tape in centimeters as the widest value between the mar-
gin of lower limb and iliac crest. Blood pressure was
measured twice (5 minutes interval) using a standard
calibrated mercury sphygmomanometer on both right
and left hands after the participants had been sitting for
at least 10 minutes. The highest blood pressure of two
sides was considered as blood pressure. Lipid profiles
(total cholesterol >200 mg/dl, low density lipoprotein
>100 mg/dl, and triglyceride >150 mg/dl) were consid-
ered as hyperlipidemia according to NCEP ATP III
guidelines [1]. Diabetes was defined when fasting blood
sugar (FBS) was ≥ 110 mg/dl or there was a history of
previous treatment for diabetes. Height was measured in
standing position and weight was measured twice with
at least clothes and without shoes for calculating BMI by
this formula: weight (kg)/height2 (m2).
Assessment of CIMT
We used high-resolution B-mode carotid ultrasound scan-
ner equipped with a linear 12 MHz transducer (My Lab 70
X Vision. Biosound Esaote, USA) for examination of the
right and left carotid arteries. The examinations were per-
formed by an expert in 12 locations as the following: Right
anterior and posterior internal carotid arteries, Left anterior
and posterior internal carotid arteries, Right anterior and
posterior carotid artery bifurcation, Left anterior and pos-
terior carotid artery bifurcation, Right anterior and poster-
ior common carotid artery, and Left anterior and posterior
common carotid artery [20]. A segment of the artery which
was most clearly visible to the examiner was magnified to
identify a distinct lumen-intima and media-adventitia
interface. CIMT was defined as the distance between the
leading edge of the lumen-intima interface and the leading
edge of the media-adventitia interface. Maximum thickness
was measured semi-automatically off-line with artery
measurement system software (Vascular tools 5, Medical
Imaging Applications LLC, USA). The cut-off point of
≥0.73 mm was considered as high risk for development of
atherosclerotic vascular disease [21].
Laboratory tests
Venous blood samples were drawn from the ante-cubital
vein after an overnight fast to measure fasting blood
sugar (FBS), total cholesterol, triglyceride, and high-
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determined enzymatically with Pars- Azmon kit/Iran.
Low-density lipoprotein (LDL) cholesterol was calcu-
lated with the Friedewald formula if triglyceride level
was met <400 mg/dl [22]; it was measured directly in
participants whose triglyceride was ≥400 mg/dl.
Statistical analyses
The normality of distribution of data was evaluated by
Kolmogrov-Smirnov test. All obtained values were expressed
as mean±standard deviation (SD). Paired T-Test was ap-
plied for variables with normal distribution, and Wilcoxon
and Mann–Whitney nonparametric tests for other variables.
Univariate and multivariate logistic regression models were
performed to examine association between Mets and con-
ventional risk factors of CVD with CIMT separately in men
and women. Statistical analyses were performed using
SPSS, version 15.0 and P value ≤0.05 was considered as
statistically significant.
Results
Majority of the participants [87 (58%)] were females. Preva-
lence of hyperlipidemia (hypertriglyceridemia +hyperchol-
esterolemia) and hypertension was 126 (84%) and 66
(44%), respectively. Within participants with MetS, the per-
cent of MetS components was as follow: 10% without com-
ponent, 22.7% one component, 20% two components,
20.7% three components, 21.3% four components, and
5.3% five components. Table 1 shows the baselineTable 1 Baseline characteristics of 150 participants with
and without MetS
Variable Non-MetS group MetS group P Value
n= 79 n= 71
(mean± SD) (mean± SD)
age (yr) 49.2 ± 8.2 50.5 ± 6.7 0.32
Sex (M/F) (n (%)) 24(16%)/55(36.7%) 39(26%)/32(21.3%) 0.003*
BMI (kg/m2) 27.8 ± 4.6 29.1 ± 3.8 0.03*†
WC (cm) 87.4 ± 10.7 97.1 ± 8.2 <0.001*†
SBP (mmHg) 118 ± 14 135 ± 15 <0.001*
DBP (mmHg) 74 ± 9 82± 11 <0.001*
FBS (mg/dl) 89 ± 9 100 ± 12 <0.001*†
TChol (mg/dl) 196 ± 35 205 ± 33 0.10
TG (mg/dl) 128 ± 57 197 ± 85 <0.001*†
LDL (mg/dl) 110 ± 23 118 ± 22 0.01*†
HDL (mg/dl) 50 ± 10 42 ± 9 <0.001*†
CIMT (mm) 0.60 ± 0.11 0.69 ± 0.16 0.001*†
Legend: M/F: Male/Female, BMI: Body Mass Index, WC: Waist Circumference,
SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure, FBS: Fasting Blood
Sugar, TChol: Total Cholesterol, TG: Triglyceride, LDL: Low Density lipoprotein,
HDL: High Density Lipoprotein, CIMT: Carotid artery Intima Media Thickness.
*P≤ 0.05 was considered statistically significant.
†Analytic test was Mann–Whitney Test. In others the analytic test was T-Test.characteristics of participants with and without MetS. We
found in regression analysis that is an interaction with sex
in the association between MetS and CIMT. The statistical
difference (p) among men was 0.053 and among women
was <0.001. Results of univariate and multivariate regres-
sion models separately in men and women are shown in
Table 2, and Table 3, respectively.
Discussion
We found that CIMT in asymptomatic middle-aged
adults with MetS was higher than those without MetS
(p = 0.001). Furthermore, regression analyses for conven-
tional risk factors both unadjusted and adjusted, indi-
cated that this association was significant only in women
(p = 0.002, p = 0.011, respectively). These findings high-
light the importance of an increased burden of subclin-
ical atherosclerosis in middle-aged women with MetS
and suggest the presence of an increased risk of future
CVD in this group. It has been shown that patients with
MetS are at increased risk for development of vascular
abnormalities ranged from endothelial dysfunction, fol-
lowed by artery stiffness to evident atherosclerosis [23].
A meta-analysis showed that subjects with MetS have
61% higher risk of CVD than those without MetS [24].
Several cross-sectional studieshave showna significantas-
sociation between CIMTand MetS [11-13,25]. Hulthe et al
[10] reported an association between MetS with acceler-
ated atherosclerosis in asymptomatic middle-aged adults.
The Botnia Study demonstrated that middle-aged adultsTable 2 Association between CIMT and MetS in men by





Value(CI 95%) (CI 95%)
MetS (yes/no) 1.833 0.364 0.319 0.462
(0.496-6.778) (0.015-6.707)
Age (yr) 1.112 0.015* 1.223 0.005*
(1.021-1.211) (1.062-1.408)
BMI (kg/m2) 1.077 0.339 1.182 0.364
(0.925-1.255) (0.824-1.697)
WC (cm) 1.018 0.537 0.941 0.399
(0.962-1.078) (0.818-1.083)
Diabetes (yes/no) 1.312 0.656 1.629 0.604
(0.397-4.338) (0.258-10.288)
Hyperlipidemia (yes/no) 6.000 0.101 49.363 0.045*
(0.707-50.920) (1.100-2215.205)
Hypertension (yes/no) 1.500 0.509 5.263 0.114
(0.450-5.003) (0.672-41.247)
Legend: MetS: Metabolic syndrome, BMI: Body Mass Index, WC: Waist
Circumference, CI 95%: Confidence Interval 95%.
*P≤ 0.05 was considered statistically significant in Binary regression models.
Table 3 Association between CIMT and MetS in women





Value(CI 95%) (CI 95%)
MetS (yes/no) 6.750 0.002* 14.223 0.011*
(2.055-22.167) (1.828-110.649)
Age (yr) 1.115 0.012* 1.208 0.014*
(1.024-1.213) (1.039-1.404)
BMI (kg/m2) 0.951 0.426 0.792 0.106
(0.839-1.077) (0.597-1.051)
WC (cm) 1.021 0.444 0.970 0.649
(0.968-1.076) (0.849-1.107)
Diabetes (yes/no) 1.035 0.154 0.811 0.820
(0.987-1.086) (0.133-4.941)
Hyperlipidemia (yes/no) 2.415 0.422 0.666 0.746
(0.281-20.790) (0.057-7.810)
Hypertension (yes/no) 3.697 0.022* 1.769 0.475
(1.211-11.291) (0.370-8.463)
Legend: MetS: Metabolic syndrome, BMI: Body Mass Index, WC: Waist
Circumference, CI 95%: Confidence Interval 95%.
*P≤ 0.05 was considered statistically significant in Binary regression models.
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of incident CVD [26]. The Bogalusa Heart Study [27]
reported that MetS, defined by either NCEP ATP III or
WHO criteria, was associated with increased CIMT.
We chose NCEP ATP III criteria for definition of MetS
due to its easy applicability to clinical practice and epi-
demiological studies. In addition, in this method we do
not require insulin measurement, albumin assessment in
urine or oral glucose tolerance test (OGTT) as needed
for definition MetS according to WHO [28]. So, the
NCEP ATP III criteria may be less sensitive than the
WHO criteria in predicting T2DM [29]. In contrast, it
was found that subjects with MetS according to NCEP
ATP III criteria were less insulin resistant and at higher
risk for future CVD than subjects with MetS by WHO
definition [30]. Because of differing definitions of MetS
in various articles, comparison with previous studies is
difficult. The Atherosclerosis and Insulin Resistance
Study showed that middle-aged white men with MetS
according to WHO criteria had increased CIMT [10],
whereas the Brunek Study demonstrated that CIMT was
significantly higher in middle-aged and elderly adults
with MetS according to NCEP ATP III and modified
WHO definitions [3]. By other diagnostic criteria includ-
ing International Diabetes Federation (IDF) and Ameri-
can Heart Association/National Heart, Lung, and Blood
Institute (AHA/NHLBI), the sex differences in associ-
ation between CIMT and MetS were not homogenous
[13]. However, irrespective of definition, CIMT wassignificantly higher in both men and women with MetS
than those without MetS [13].
The gender difference association between MetS and
CIMT in our study was in line with findings of Iglseder
et al [14] who also found this significant association only
in women. This finding may be due to higher levels of
C - reactive protein (CRP) and inflammatory markers in
pre-menopausal women [31]. Higher levels of fasting
leptin and lower insulin sensitivity in pre-menopausal
women may also play a role in this context [32].
On the other hand, the results of study by Skilton et al
[13] showed no sex differences in the association
between MetS and CIMT by NCEP ATP III criteria,
although this relation was apparent when they used other
criteria for definition of MetS [13]. This finding stipulates
that female protection against atherosclerosis is lost in the
presence of MetS. This suggestion is supported by identifi-
cation of sex-specific and sex-independent quantitative
trait loci for MetS components in animal studies [33]. It is
also supported by observation of the influence of sex on
several components of MetS among male and female
twins [34].
When we assessed the effect of MetS on CIMT after
adjusting for traditional cardiovascular risk factors in the
multivariate regression model, MetS was a significant inde-
pendent predictor of CVD only in women (p=0.011). We
found some differences between both sexes in traditional
risk factors affecting CIMT. As expected, age was the
strongest determinant of CIMT in both sexes. This finding
is in line with previous studies [11,35]. Hyperlipidemia was
another determinant which was effective only in men with.
The Atherosclerosis Risk in Communities (ARIC) study [7]
demonstrated an association between CIMT and incidence
of MI even after adjusting for age, race, diabetes, choles-
terol, hypertension and smoking in a large population
study of middle-aged adults. In addition, the Cardiovascu-
lar Health Study showed a significant association between
CIMT and risk for CVD after adjusting for traditional risk
factors [36]. In the Muscatine Study, multivariate analysis
showed that CIMT was associated with systolic blood pres-
sure, increasing age, and LDL in women and with smoking
in men [37]. In the Health 2000 Survey [9] it was found
that BMI, WC, LDL, total cholesterol and diastolic blood
pressure had statistically significant univariate correlation
with CIMT in women but not in men. However, our
results suggested that MetS screening in hyperlipidemic
men provides more benefit than women to identify sub-
jects at risk for CVD. This finding may be related to
gender-specific differences in the association between LDL
cholesterol and atherosclerosis [38]. However, we cannot
address any cause and effect relationship regarding the
effect of hyperlipidemia on CIMT due to cross-sectional
nature of our study. Furthermore, most subjects were
being under treatment with several types of medications
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on vascular function to halt the progression or even
reduce CIMT [39].
Our study had several limitations. Because our study
was carried out in a small population, the observed
effects may not be applicable to the general population.
In some studies it has been observed that CIMT
increases with increasing number of MetS components
[40-42]. This supports the hypothesis that declares clus-
tering of MetS components has an additive effect on
progression of CIMT [41]. However, we were not able to
investigate this hypothesis in our study due to limitation
in sample size. Thus, prospective studies are required to
determine the ability of each component of MetS to pre-
dict the occurrence of cardiovascular events in women.
Conclusion
It seems that MetS provides useful information of the
patient’s cardiovascular risk in addition to the traditional
risk factors. The burden of subclinical atherosclerosis
increases in middle-aged with MetS. In addition, increasing
age and presence hyperlipidemia are strong predictors of
increased CIMT. We suggest the assessment of CIMT
along with identification of individuals with MetS to pro-
vide appropriate intervention for prevention of CVD in
middle-aged individuals especially in old women.
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